Clinical Trial Summary Survey Study

Thank you for participating in this survey. We have used artificial intelligence to help write short summaries of clinical trials as a new educational resource for patients. In this survey, we would like your input on how helpful and understandable the summaries would be if used as a resource for patients to learn about their clinical trial options.

This survey should take you between 10-15 minutes, and all questions are optional. While you will not be compensated for your time, we hope to use the information we gather during this study to improve communication methods for future research studies.

Before you begin, we would like to collect some information about you. Please remember that all questions are entirely optional.

What is your age?

- ◯ 18-20 years
- ◯ 21-30 years
- ◯ 31-40 years
- ◯ 41-50 years
- ◯ 51-60 years
- ◯ 61-70 years
- ◯ 71-80 years
- ◯ 81-90 years
- ◯ Over 90 years
- ◯ Prefer not to say

What gender best describes you?

- ◯ Woman
- ◯ Man
- ◯ Gender fluid
- ◯ Genderqueer
- ◯ Agender
- ◯ Nonbinary
- ◯ Unsure
- ◯ Prefer not to say
- ◯ Another

Please specify your gender

_____

How would you best describe yourself?

- ☐ American Indian or Alaska Native
- ☐ Asian
- ☐ Black or African American
- ☐ Native Hawaiian or Other Pacific Islander
- ☐ White
- ☐ Prefer not to say
- ☐ Another

Please specify your race

_____

Are you Hispanic/Latino/Spanish origin?

- ◯ Yes
- ◯ No
- ◯ Prefer not to say

Have you previously participated in a clinical trial?

- ◯ Yes
- ◯ No
- ◯ Unsure
- ◯ Prefer not to say

This is the summary for BROADBAND, the study for which you had the consent discussion:

We're inviting patients to join a research study called BROADBAND. This study aims to collect and store blood, urine, and tissue samples from patients. These samples, along with participant's health information, will be used for research to improve radiation therapy and other treatments for cancer and various diseases. By understanding how different factors affect health, we hope to develop new tests and treatments. If a patient agrees to participate, they'll donate a small amount of blood before their treatment starts, and possibly more samples during and after treatment. We might also use samples collected during regular care that would otherwise be discarded. Participation also involves allowing us to access your medical records. This study won't change standard care, and patients can choose to stop participating at any time without affecting your medical care. Participating in this study is voluntary. If a patient decides not to participate or to withdraw later, it won't impact their current or future care. There are minimal risks involved, mainly related to privacy and the physical act of drawing blood. While there's no direct benefit to participants, their participation could help improve treatments for future patients. Patients won't be paid for participating, but they'll be contributing valuable information that could lead to significant medical advancements.

Were there topics you found hard to understand during the BROADBAND consent discussion?

- ☐ Purpose of the study
- ☐ Study procedures
- ☐ Duration of participation
- ☐ Risks of participating
- ☐ Benefits of participating
- ☐ Whether the study is voluntary
- ☐ Alternatives to participating
- ☐ Other

If other, please describe.

_____

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
This summary is easy to understand.	◯	◯	◯	◯	◯
I believe that reading this summary improved my understanding of BROADBAND.	◯	◯	◯	◯	◯
If I were researching trials, this summary provides enough information for me to decide if I would want to contact the research team to learn more about the trial.	◯	◯	◯	◯	◯

Please provide any additional information you think should be included in the summary.

_____

The summaries on the following pages are about trials that are not specific to you.

Trial 2 Summary, Version 1:

This research study is about testing a new way to treat non-small cell lung cancer by adding a drug called pembrolizumab to the usual chemotherapy treatment. The goal is to see if this combination can lower the chance of cancer coming back. If a patient decides to join, they'll either receive chemotherapy for about 3 months followed by pembrolizumab for up to 1 year, or both treatments for 3 months followed by pembrolizumab for up to 9 months. Participants' health will be checked regularly for 10 years after treatment. Joining this study is completely up to the patient, and they can leave at any time without affecting your medical care. The risks include possible side effects from pembrolizumab, which might be different or worse than those from usual treatments. However, there's a chance this treatment could help the cancer better than the usual approach. If a patient chooses not to join, they can still receive the standard treatment for their cancer or look for another study. This study aims to see if a short course of Dexamethasone, a steroid, can make immunotherapy more effective for patients with Non-Small Cell Lung Cancer (NSCLC) who have stopped responding to treatment. Participants will undergo additional scans and blood tests, and take Dexamethasone before their first three immunotherapy infusions. The study could last up to 6 years. There are risks, including the possibility that the treatment might not work or could weaken the immune system, but there's also the potential benefit of the immunotherapy working better. Joining the study is completely voluntary, and choosing not to participate won't affect patients' medical care. If patients decide not to join, other treatment options, palliative care, or hospice care might be right for them. Patients' privacy will be protected, and you'll be given a copy of the consent form for their records. Participants can ask questions at any time and withdraw from the study if they wish.

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
This summary is easy to understand.	◯	◯	◯	◯	◯
If I were researching trials, this summary provides enough information for me to decide if I would want to contact the research team to learn more about the trial.	◯	◯	◯	◯	◯

Please provide any additional information you think should be included in the summary.

Here is another version of the summary:

Trial 2 Summary, Version 2:
Purpose of the study: This research study is about testing a new way to treat non-small cell lung cancer by adding a drug called pembrolizumab to the usual chemotherapy treatment. The goal is to see if this combination can lower the chance of cancer coming back.

Description of study procedures: If a patient decides to join, they'll either receive chemotherapy for about 3 months followed by pembrolizumab for up to 1 year, or both treatments for 3 months followed by pembrolizumab for up to 9 months.

Duration of participation: Participants' health will be checked regularly for 10 years after treatment.

Risks of participating: The risks include possible side effects from pembrolizumab, which might be different or worse than those from usual treatments.

Benefits of participating: There's a chance this treatment could help the cancer better than the usual approach.

Voluntary: Joining this study is completely up to the patient, and they can leave at any time without affecting your medical care.

Alternatives: If a patient chooses not to join, they can still receive the standard treatment for their cancer or look for another study.

Which version of the trial do you prefer?

◯ Version 1 (paragraph)
◯ Version 2 (list)
◯ No preference

Trial 3 Summary:

This study aims to see if a short course of Dexamethasone, a steroid, can make immunotherapy more effective for patients with Non-Small Cell Lung Cancer (NSCLC) who have stopped responding to treatment. Participants will undergo additional scans and blood tests, and take Dexamethasone before their first three immunotherapy infusions. The study could last up to 6 years. There are risks, including the possibility that the treatment might not work or could weaken the immune system, but there's also the potential benefit of the immunotherapy working better. Joining the study is completely voluntary, and choosing not to participate won't affect patients' medical care. If patients decide not to join, other treatment options, palliative care, or hospice care might be right for them. Patients' privacy will be protected, and you'll be given a copy of the consent form for their records. Participants can ask questions at any time and withdraw from the study if they wish.

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
This summary is easy to understand.	◯	◯	◯	◯	◯
If I were researching trials, this summary provides enough information for me to decide if I would want to contact the research team to learn more about the trial.	◯	◯	◯	◯	◯

Please provide any additional information you think should be included in the summary.

Trial 4 Summary:

This study is titled "Mobile App Utilization for Enhanced Post-Operative Nutritional Recovery". It aims to explore if a digital food diary online app, MyPlate Calorie Counter, can help people with gastrointestinal cancer meet their nutritional goals after surgery. Participants will use the online app to track their food, water intake, and physical activity for 2 months. They will see a dietician before and after surgery as part of their care. The study seeks to improve recovery quality by ensuring dietary recommendations are followed. Participation is voluntary, and there are alternatives available for those who choose not to participate, including other studies or standard care without study involvement. There are minimal risks, mainly related to privacy, and potential benefits include better management of nutritional intake post-surgery. Costs associated with regular medical care will apply, but the app is free to download, though data usage charges may apply. Participants can withdraw at any time without affecting their standard medical care.

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
This summary is easy to understand.	◯	◯	◯	◯	◯
If I were researching trials, this summary provides enough information for me to decide if I would want to contact the research team to learn more about the trial.	◯	◯	◯	◯	◯

Please provide any additional information you think should be included in the summary.

_____

Trial 5 Summary:

This study is exploring a new way to treat pancreatic cancer by adding a drug called dapagliflozin to the usual chemotherapy. Dapagliflozin is typically used for diabetes and heart failure, but it might also help fight cancer by changing how the body uses sugar, which could starve the cancer cells. If a patient joins, they'll take dapagliflozin daily for up to 8 weeks, have regular check-ups, and do some tests at home. Participation is completely up to them, and they can leave the study at any time. While there may not be direct benefits to participants, their involvement could help others in the future by improving cancer treatment. The main risks include dehydration, yeast infections, and a condition called ketoacidosis. Participants' health insurance will likely cover the cost of treatments similar to standard care, but they might have some out-of-pocket expenses. Participants' personal information will be kept private. If a participant decides not to participate, they can still receive standard cancer treatments, join another study, choose no treatment, or opt for comfort care.

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
This summary is easy to understand.	◯	◯	◯	◯	◯
If I were researching trials, this summary provides enough information for me to decide if I would want to contact the research team to learn more about the trial.	◯	◯	◯	◯	◯

Please provide any additional information you think should be included in the summary.

_____

Thank you for participating in this study. If you are using the Chromebook given to you by a staff member, please return it to the front desk or the study staff member who gave it to you. If filling out the paper version, please mail back using the included pre-addressed stamped envelope, or return in person to a study staff member